X

Trial Profile

IMaging of cancer imMUNOtherapy targets with Positron Emission Tomography: Characterising PD-L1 with 89Zr- Durvalumab (MEDI4736)

Status: Recruiting

Phase of Trial: Phase 0

Latest Information Update: 16 Sep 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Durvalumab (Primary)
Indications Non-small cell lung cancer
Focus First in man; Pharmacokinetics
Acronyms ImmunoPET

Most Recent Events

09 Aug 2022 Results (n=4) assessing the safety and optimum scanning protocol of DFO-Sq-durvalumab tracer in patients with non-small cell lung cancer, presented at the 2022 World Conference on Lung Cancer.
09 Aug 2022 Results presented at the 2022 World Conference on Lung Cancer
09 Aug 2022 Planned number of patients changed from 5 to 25

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com